Genexpert-a game-changer for tuberculosis control?

PLoS Medicine

Volumn 8, Issue 7, 2011, Pages

  Evans, Carlton A ^a,b,c  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IFHAD: Innovation For Health And Development   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT; BACTERIAL DNA;

ANALYTICAL EQUIPMENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM EXAMINATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DRUG COST; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FALSE POSITIVE RESULT; HEALTH CARE COST; HUMAN; LOWEST INCOME GROUP; MOLECULAR DIAGNOSIS; MTB RIF TEST; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POVERTY; SCREENING TEST; SOCIAL ASPECT; SPUTUM SMEAR; TUBERCULOSIS CONTROL; CLASSIFICATION; COMPARATIVE STUDY; DIAGNOSTIC TEST; DRUG EFFECT; EVALUATION; GENETICS; HOSPITAL INFORMATION SYSTEM; INSTRUMENTATION; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; METHODOLOGY; MICROBIOLOGY; NUCLEIC ACID AMPLIFICATION; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; DIAGNOSTIC TESTS, ROUTINE; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POINT-OF-CARE SYSTEMS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 79960923478     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001064     Document Type: Article

References (33)

1. World Health Organization (2010) Global tuberculosis control Geneva World Health Organization.
2. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363 (11): 1005-1015.
3. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377 (9776): 1495-1505.
4. Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, et al. (2010) MDR tuberculosis-critical steps for prevention and control. N Engl J Med 363 (11): 1050-1058.
5. Cox H, Kebede Y, Allamuratova S, Ismailov G, Davletmuratova Z, et al. (2006) Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med 3 (10): e384 doi:10.1371/journal.pmed.0030384.
6. Chaudhary M, Gupta S, Khare S, Lal S, (2010) Diagnosis of tuberculosis in an era of HIV pandemic: a review of current status and future prospects. Indian J Med Microbiol 28 (4): 281-289.
7. Wilson ML, (2011) Recent advances in the laboratory detection of Mycobacterium tuberculosis complex and drug resistance. Clin Infect Dis 52 (11): 1350-1355.
8. Helb D, Jones M, Story E, Boehme C, Wallace E, et al. (2010) Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48 (1): 229-237.
9. Small PM, Pai M, (2010) Tuberculosis diagnosis-time for a game change. N Engl J Med 363 (11): 1070-1071.
10. Blakemore R, Story E, Helb D, Kop J, Banada P, et al. (2010) Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 48 (7): 2495-2501.
11. Lawn SD, Brooks SV, Kranzer K, Nicol M, Whitelaw A, et al. (2011) Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8 (7): e1001067 doi:10.1371/journal.pmed.1001067.
12. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, et al. (2011) Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 8 (7): e1001061 doi:10.1371/journal.pmed.1001061.
13. Dowdy DW, (2011) Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med 8 (7): e1001063 doi:10.1371/journal.pmed.1001063.
14. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W, (2010) Xpert((R)) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn 10 (7): 937-946.
15. Pai M, Ramsay A, O'Brien R, (2008) Evidence-based tuberculosis diagnosis. PLoS Med 5 (7): e156 doi:10.1371/journal.pmed.0050156.
16. World Health Organization (2004) Respiratory care in primary care services - a survey in 9 countries. Practical Approach to Lung Health (PAL) Geneva World Health Organization.
17. Otero L, Ugaz R, Dieltiens G, Gonzalez E, Verdonck K, et al. (2010) Duration of cough, TB suspects' characteristics and service factors determine the yield of smear microscopy. Trop Med Int Health 15 (12): 1475-1480.
18. Hinderaker SG, Rusen ID, Chiang CY, Yan L, Heldal E, et al. (2011) The FIDELIS initiative: innovative strategies for increased case finding. Int J Tuberc Lung Dis 15 (1): 71-76.
19. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Available: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf. Accessed 24 June 2011.
20. Kawai V, Soto G, Gilman RH, Bautista CT, Caviedes L, et al. (2006) Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg 75 (6): 1027-1033.
21. Stall N, Rubin T, Michael JS, Mathai D, Abraham OC, et al. (2011) Does solid culture for tuberculosis influence clinical decision making in India? Int J Tuberc Lung Dis 15 (5): 641-646.
22. Edginton ME, Miller DL, Burney P, El Sony AI, Lwilla FI, et al. (2010) Surveillance for MDR-TB: is there an obligation to ensure treatment for individuals identified with MDR-TB? Int J Tuberc Lung Dis 14 (9): 1094-1096.
23. Furin J, Bayona J, Becerra M, Farmer P, Golubkov A, et al. (2011) Programmatic management of multidrug-resistant tuberculosis: models from three countries. Int J Tuberc Lung Dis 15 (7) E-pub ahead of print 8 June 2011. doi:10.5588/ijtld.10.0591.
24. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, et al. (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348 (2): 119-128.
25. Resch SC, Salomon JA, Murray M, Weinstein MC, (2006) Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3 (7): e241 doi:10.1371/journal.pmed.0030241.
26. Martinez D, Heudebert G, Seas C, Henostroza G, Rodriguez M, et al. (2010) Clinical prediction rule for stratifying risk of pulmonary multidrug-resistant tuberculosis. PLoS ONE 5 (8): e12082 doi:10.1371/journal.pone.0012082.
27. World Health Organization STOP TB Department (2010) Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Available: http://www.who.int/tb/laboratory/roadmap_xpert_mtb-rif.pdf. Accessed 24 June 2011.
28. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, et al. (2010) Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 375 (9728): 1814-1829.
29. Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M, (2009) Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ 87 (9): 683-691.
30. Oxlade O, Schwartzman K, Behr MA, Benedetti A, Pai M, et al. (2009) Global tuberculosis trends: a reflection of changes in tuberculosis control or in population health? Int J Tuberc Lung Dis 13 (10): 1238-1246.
31. Benatar SR, Upshur R, (2010) Tuberculosis and poverty: what could (and should) be done? Int J Tuberc Lung Dis 14 (10): 1215-1221.
32. Rasanathan K, Sivasankara Kurup A, Jaramillo E, Lönnroth K, (2011) The social determinants of health: key to global tuberculosis control. Int J Tuberc Lung Dis 15 (Supplement 2): S30-S36.
33. Creswell J, Jaramillo E, Lonnroth K, Weil D, Raviglione M, (2011) Tuberculosis and poverty: what is being done. Int J Tuberc Lung Dis 15 (4): 431-432.